Clinically, FSH–Gonadotropin-Releasing Hormone pulse therapy exploits this by transiently lowering circulating FSH to induce monofollicular growth, thereby minimizing ovarian hyperstimulation syndrome and multiple pregnancies. Here, BRD2 is linked to ovarian hyperstimulation syndrome.